FDA CBER Patient Listening Meeting on Gene Therapy Safety: Patient and Care Partner Perspectives

The FDA CBER Patient Listening Meeting on September 20, 2024, put rare-disease patients and care partners at the center of gene therapy safety discussions. CBER used the virtual session to hear how people weigh short- and long-term risks, what information they need before treatment, and how they experience long-term follow-up after approved gene therapies.

Key Takeaways

• FDA CBER Patient Listening Meeting (Meeting 1) ran virtually on Sept 20, 2024, from 11:00 a.m. to 4:30 p.m. ET.
• Agenda themes: treatment-decision safety information and partnering on long-term post-gene-therapy studies.
• FDA reported 19 gene therapy approvals as of June 2024, after the first approval in 2017.
• A second listening meeting on Dec 4, 2024, focused on early enrollment into gene therapy trials.

What was the FDA CBER Patient Listening Meeting?

CBER convened Meeting 1 as a public Zoom listening session, not an advisory committee vote. The agency’s stated goal was to understand patient and care partner perspectives on approved gene therapy products for rare diseases. Official logistics and objectives are posted on the FDA Meeting 1 page.

Why did CBER focus on safety after approval?

Clinical trials that support approval define risks and benefits at launch, but long-term adverse events may appear only afterward. FDA’s listening-meeting hub explains that post-approval data come from long-term observation of trial participants, post-marketing studies, and reports from patients, manufacturers, and clinicians. See the 2024 CBER patient listening meetings hub.

What questions shaped the agenda?

FDA organized the day around two practical themes for patients and caregivers.

• What short- and long-term risks matter most when deciding on an approved gene therapy?
• What information formats help people understand those risks?
• What factors shape willingness to join registries or other long-term studies?
• How should long-term studies be designed, operated, and communicated?

Introductory polling captured demographics, knowledge levels, and preferred channels for risk information, according to FDA’s meeting framing materials.

How does this fit the broader gene therapy setting?

FDA noted gene therapy has become an option for some rare diseases with unmet need, with 19 approved products as of June 2024. Product-class context for cellular and gene therapies is maintained under FDA’s biologics resources, including the cellular and gene therapy products page.

What followed Meeting 1?

Meeting 2 on December 4, 2024, shifted to early enrollment into gene therapy clinical trials for rare diseases, including pre-symptomatic or early symptomatic stages. That session had a separate docket and comment window. Sponsors and patient groups should treat both meetings as qualitative input for protocol design, not as binding regulatory guidance.

What should sponsors and patient groups do with the input?

Medical affairs and patient advocacy teams can map listening-meeting themes to informed-consent language, registry invitation scripts, and long-term follow-up visit schedules. The September 20, 2024 session ran about five and a half hours, which is enough time for structured polling plus two deep-dive discussion blocks, but not enough to replace disease-specific advisory meetings.

When drafting protocols, treat Meeting 1 comments as hypotheses about what patients want communicated after year one, year five, and beyond. Confirm any safety messaging against the approved label and against CBER guidance for gene therapy long-term follow-up rather than against meeting minutes alone.

What remains unproven

Listening-meeting comments are not randomized evidence and do not change product labels by themselves. Polling results and public comments inform FDA’s understanding of patient priorities; they do not quantify risk magnitudes for individual gene therapy products. Sponsors still need formal post-marketing commitments and pharmacovigilance data for labeled safety claims.

Related NovaPharma coverage

• FDA Approves First CRISPR Gene Therapy for Sickle Cell Disease
• $2M Gene Therapy Cures Need a Financing Model
• uniQure AMT-130 Gene Therapy Advances Toward UK Approval for Huntington's Disease

Frequently Asked Questions

When was the FDA CBER Patient Listening Meeting on gene therapy safety held?

Meeting 1 was held virtually on September 20, 2024, from 11:00 a.m. to 4:30 p.m. ET. FDA framed it as a public patient and care partner listening meeting on safety considerations for approved gene therapy treatments for rare diseases.

What topics did the FDA CBER Patient Listening Meeting cover?

FDA sought patient and care partner views on short- and long-term risks of approved gene therapies, information needed for treatment decisions, experience with post-market long-term follow-up studies, and input to inform patient-centered long-term study protocols.

How many gene therapies had FDA approved by mid-2024?

On its 2024 CBER listening-meeting hub, FDA noted the first gene therapy approval in 2017 and 19 gene therapies approved as of June 2024, many for rare diseases, while stressing ongoing post-approval safety data collection.

Primary Sources

1. FDA: Meeting 1 gene therapy safety listening meeting (Sept 20, 2024)
2. FDA: 2024 CBER patient and care partner listening meetings
3. FDA: Cellular and gene therapy products